| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.87 [0.66, 1.14] | | < 1 | | 0% | 1 study (1/-) | 84.1 % | NA | not evaluable | | crucial | - |
| MFS | 0.73 [0.56, 0.96] | | < 1 | | 0% | 1 study (1/-) | 98.8 % | NA | not evaluable | | important | - |
| RFS (extension) | 0.71 [0.59, 0.85] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| RFS/DFS | 0.92 [0.45, 1.89] | | < 1 | | 86% | 3 studies (3/-) | 59.3 % | low | not evaluable | high | important | - |
safety endpoints 00 |
| AE (any grade) | 0.49 [0.20, 1.23] | | < 1 | | 0% | 1 study (1/-) | 93.6 % | NA | not evaluable | | non important | - |
| AE (grade 3-4) | 0.28 [0.21, 0.37] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 0.95 [0.06, 15.45] | | < 1 | | 0% | 2 studies (2/-) | 51.3 % | low | not evaluable | high | non important | - |
| AE leading to treatment discontinuation (any grade) | 0.29 [0.07, 1.26] | | < 1 | | 87% | 3 studies (3/-) | 95.0 % | low | not evaluable | high | non important | - |
| AE leading to treatment discontinuation (grade 3-4) | 0.24 [0.05, 1.09] | | < 1 | | 83% | 3 studies (3/-) | 96.8 % | low | not evaluable | high | non important | - |
| SAE (any grade) | 0.58 [0.13, 2.64] | | < 1 | | 86% | 2 studies (2/-) | 75.7 % | low | not evaluable | high | non important | - |
| SAE (grade 3-4) | 0.83 [0.10, 6.97] | | < 1 | | 91% | 2 studies (2/-) | 56.7 % | low | not evaluable | high | non important | - |
| STRAE (any grade) | 0.97 [0.03, 31.56] | | < 1 | | 93% | 2 studies (2/-) | 50.6 % | low | not evaluable | high | non important | - |
| STRAE (grade 3-4) | 1.64 [0.02, 132.78] | | < 1 | | 88% | 2 studies (2/-) | 41.5 % | low | not evaluable | high | non important | - |
| TRAE (any grade) | 0.62 [0.08, 4.75] | | < 1 | | 93% | 3 studies (3/-) | 67.8 % | low | not evaluable | high | non important | - |
| TRAE (grade 3-4) | 0.49 [0.10, 2.37] | | < 1 | | 92% | 3 studies (3/-) | 81.1 % | low | not evaluable | high | non important | - |
| TRAE leading to death (grade 5) | 0.52 [0.07, 4.17] | | < 1 | | 0% | 3 studies (3/-) | 72.8 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (any grade) | 0.28 [0.06, 1.28] | | < 1 | | 86% | 3 studies (3/-) | 94.9 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 0.19 [0.04, 0.88] | | < 1 | | 80% | 3 studies (3/-) | 98.3 % | low | not evaluable | high | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.73 [0.08, 6.31] | | < 1 | | 0% | 3 studies (3/-) | 61.1 % | low | not evaluable | high | non important | - |
| Acute kidney injury TRAE (grade 3-4) | 0.64 [0.05, 8.40] | | < 1 | | 0% | 2 studies (2/-) | 63.3 % | low | not evaluable | high | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 0.54 [0.13, 2.22] | | < 1 | | 0% | 3 studies (3/-) | 80.4 % | low | not evaluable | high | non important | - |
| Alopecia TRAE (grade 3-4) | 0.95 [0.06, 15.31] | | < 1 | | 0% | 2 studies (2/-) | 51.6 % | low | not evaluable | high | non important | - |
| Anaemia TRAE (grade 3-4) | 0.64 [0.05, 8.40] | | < 1 | | 0% | 2 studies (2/-) | 63.3 % | low | not evaluable | high | non important | - |
| Arthralgia TRAE (grade 3-4) | 1.52 [0.30, 7.73] | | < 1 | | 0% | 3 studies (3/-) | 30.7 % | low | not evaluable | high | non important | - |
| Asthenia TRAE (grade 3-4) | 0.25 [0.03, 2.24] | | < 1 | | 0% | 1 study (1/-) | 89.1 % | NA | not evaluable | | non important | - |
| Blood and lymphatic system disorders TRAE (grade 3-4) | 2.98 [0.27, 32.69] | | < 1 | | 0% | 2 studies (2/-) | 18.8 % | low | not evaluable | high | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 0.91 [0.02, 46.72] | | < 1 | | 0% | 1 study (1/-) | 51.8 % | NA | not evaluable | | non important | - |
| Chills TRAE (grade 3-4) | 0.95 [0.06, 15.31] | | < 1 | | 0% | 2 studies (2/-) | 51.6 % | low | not evaluable | high | non important | - |
| Colitis TRAE (grade 3-4) | 0.30 [0.03, 3.29] | | < 1 | | 0% | 2 studies (2/-) | 83.6 % | low | not evaluable | high | non important | - |
| Cough TRAE (grade 3-4) | 0.95 [0.06, 15.31] | | < 1 | | 0% | 2 studies (2/-) | 51.6 % | low | not evaluable | high | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.95 [0.06, 15.31] | | < 1 | | 0% | 2 studies (2/-) | 51.6 % | low | not evaluable | high | non important | - |
| Diabetes TRAE (grade 3-4) | 1.94 [0.27, 13.89] | | < 1 | | 0% | 3 studies (3/-) | 25.6 % | low | not evaluable | high | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.35 [0.07, 1.69] | | < 1 | | 40% | 3 studies (3/-) | 90.4 % | low | not evaluable | high | non important | - |
| Dizziness TRAE (grade 3-4) | 0.95 [0.06, 15.31] | | < 1 | | 0% | 2 studies (2/-) | 51.6 % | low | not evaluable | high | non important | - |
| Dry skin TRAE (grade 3-4) | 0.95 [0.06, 15.31] | | < 1 | | 0% | 2 studies (2/-) | 51.6 % | low | not evaluable | high | non important | - |
| Dysgeusia TRAE (grade 3-4) | 0.95 [0.06, 15.31] | | < 1 | | 0% | 2 studies (2/-) | 51.6 % | low | not evaluable | high | non important | - |
| Dyspepsia TRAE (grade 3-4) | 0.95 [0.06, 15.31] | | < 1 | | 0% | 2 studies (2/-) | 51.6 % | low | not evaluable | high | non important | - |
| Dyspnoea TRAE (grade 3-4) | 0.95 [0.06, 15.31] | | < 1 | | 0% | 2 studies (2/-) | 51.6 % | low | not evaluable | high | non important | - |
| Endocrine disorders TRAE (grade 3-4) | 0.39 [0.05, 3.31] | | < 1 | | 20% | 2 studies (2/-) | 80.4 % | low | not evaluable | high | non important | - |
| Eye disorders TRAE (grade 3-4) | 0.64 [0.05, 8.40] | | < 1 | | 0% | 2 studies (2/-) | 63.3 % | low | not evaluable | high | non important | - |
| Fatigue TRAE (grade 3-4) | 0.59 [0.14, 2.54] | | < 1 | | 0% | 3 studies (3/-) | 75.9 % | low | not evaluable | high | non important | - |
| Gastritis TRAE (grade 3-4) | 0.40 [0.03, 4.62] | | < 1 | | 0% | 2 studies (2/-) | 76.7 % | low | not evaluable | high | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 0.13 [0.04, 0.40] | | < 1 | | 25% | 3 studies (3/-) | 100.0 % | low | not evaluable | high | non important | - |
| General disorders and administration site conditions TRAE (grade 3-4) | 0.40 [0.03, 4.62] | | < 1 | | 0% | 2 studies (2/-) | 76.7 % | low | not evaluable | high | non important | - |
| Headache TRAE (grade 3-4) | 0.28 [0.05, 1.50] | | < 1 | | 0% | 3 studies (3/-) | 93.0 % | low | not evaluable | high | non important | - |
| Hepatitis TRAE (grade 3-4) | 0.74 [0.07, 7.82] | | < 1 | | 49% | 2 studies (2/-) | 59.9 % | low | not evaluable | high | non important | - |
| Hepatobiliary disorders TRAE (grade 3-4) | 0.22 [0.06, 0.77] | | < 1 | | 50% | 3 studies (3/-) | 99.1 % | low | not evaluable | high | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 2.01 [0.07, 59.97] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
| Hypertension TRAE (grade 3-4) | 0.95 [0.06, 15.31] | | < 1 | | 0% | 2 studies (2/-) | 51.6 % | low | not evaluable | high | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 0.50 [0.08, 3.08] | | < 1 | | 0% | 3 studies (3/-) | 77.1 % | low | not evaluable | high | non important | - |
| Hypophysitis TRAE (grade 3-4) | 0.46 [0.09, 2.47] | | < 1 | | 25% | 3 studies (3/-) | 81.6 % | low | not evaluable | high | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.66 [0.11, 4.05] | | < 1 | | 0% | 3 studies (3/-) | 67.4 % | low | not evaluable | high | non important | - |
| Increase AST TRAE (grade 3-4) | 0.38 [0.06, 2.20] | | < 1 | | 65% | 3 studies (3/-) | 85.9 % | low | not evaluable | high | non important | - |
| Increased ALT TRAE (grade 3-4) | 0.31 [0.08, 1.18] | | < 1 | | 57% | 3 studies (3/-) | 95.7 % | low | not evaluable | high | non important | - |
| Increased lipase level TRAE (grade 3-4) | 0.50 [0.17, 1.45] | | < 1 | | 0% | 2 studies (2/-) | 89.8 % | low | not evaluable | high | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 0.95 [0.06, 15.31] | | < 1 | | 0% | 2 studies (2/-) | 51.6 % | low | not evaluable | high | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.95 [0.06, 15.31] | | < 1 | | 0% | 2 studies (2/-) | 51.6 % | low | not evaluable | high | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 0.21 [0.03, 1.43] | | < 1 | | 0% | 3 studies (3/-) | 94.4 % | low | not evaluable | high | non important | - |
| Metabolism and nutrition disorders TRAE (grade 3-4) | 1.26 [0.14, 10.99] | | < 1 | | 0% | 2 studies (2/-) | 41.7 % | low | not evaluable | high | non important | - |
| Musculoskeletal and connective tissue disorders TRAE (grade 3-4) | 5.94 [0.70, 50.19] | | < 1 | | 0% | 2 studies (2/-) | 5.2 % | low | not evaluable | high | non important | - |
| Myalgia TRAE (grade 3-4) | 1.91 [0.17, 21.35] | | < 1 | | 0% | 2 studies (2/-) | 30.1 % | low | not evaluable | high | non important | - |
| Myositis TRAE (grade 3-4) | 0.95 [0.06, 15.31] | | < 1 | | 0% | 2 studies (2/-) | 51.6 % | low | not evaluable | high | non important | - |
| Nausea TRAE (grade 3-4) | 1.28 [0.15, 11.02] | | < 1 | | 0% | 3 studies (3/-) | 41.2 % | low | not evaluable | high | non important | - |
| Nervous system disorders TRAE (grade 3-4) | 2.53 [0.37, 17.24] | | < 1 | | 0% | 2 studies (2/-) | 17.2 % | low | not evaluable | high | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.95 [0.06, 15.31] | | < 1 | | 0% | 2 studies (2/-) | 51.6 % | low | not evaluable | high | non important | - |
| Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.95 [0.06, 15.31] | | < 1 | | 0% | 2 studies (2/-) | 51.6 % | low | not evaluable | high | non important | - |
| Pancreatitis TRAE (grade 3-4) | 0.95 [0.06, 15.31] | | < 1 | | 0% | 2 studies (2/-) | 51.6 % | low | not evaluable | high | non important | - |
| Paraesthesia TRAE (grade 3-4) | 0.95 [0.06, 15.31] | | < 1 | | 0% | 2 studies (2/-) | 51.6 % | low | not evaluable | high | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 0.64 [0.05, 8.40] | | < 1 | | 0% | 2 studies (2/-) | 63.3 % | low | not evaluable | high | non important | - |
| Pneumonitis TRAE (grade 3-4) | 0.95 [0.06, 15.31] | | < 1 | | 0% | 2 studies (2/-) | 51.6 % | low | not evaluable | high | non important | - |
| Pruritus TRAE (grade 3-4) | 0.32 [0.04, 2.41] | | < 1 | | 0% | 3 studies (3/-) | 86.4 % | low | not evaluable | high | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.33 [0.05, 2.28] | | < 1 | | 0% | 3 studies (3/-) | 86.7 % | low | not evaluable | high | non important | - |
| Rash TRAE (grade 3-4) | 0.35 [0.13, 0.98] | | < 1 | | 0% | 1 study (1/-) | 97.7 % | NA | not evaluable | | non important | - |
| Renal and urinary disorders TRAE (grade 3-4) | 1.00 [0.02, 50.62] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
| Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 0.36 [0.05, 2.74] | | < 1 | | 0% | 3 studies (3/-) | 83.6 % | low | not evaluable | high | non important | - |
| Sarcoidosis TRAE (grade 3-4) | 0.95 [0.06, 15.31] | | < 1 | | 0% | 2 studies (2/-) | 51.6 % | low | not evaluable | high | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 0.22 [0.09, 0.52] | | < 1 | | 0% | 3 studies (3/-) | 100.0 % | low | not evaluable | high | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.95 [0.06, 15.31] | | < 1 | | 0% | 2 studies (2/-) | 51.6 % | low | not evaluable | high | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.64 [0.05, 8.40] | | < 1 | | 0% | 2 studies (2/-) | 63.3 % | low | not evaluable | high | non important | - |
| Thyroiditis TRAE (grade 3-4) | 0.95 [0.06, 15.31] | | < 1 | | 0% | 2 studies (2/-) | 51.6 % | low | not evaluable | high | non important | - |
| Uveitis TRAE (grade 3-4) | 0.95 [0.06, 15.31] | | < 1 | | 0% | 2 studies (2/-) | 51.6 % | low | not evaluable | high | non important | - |
| Vitiligo TRAE (grade 3-4) | 0.95 [0.06, 15.31] | | < 1 | | 0% | 2 studies (2/-) | 51.6 % | low | not evaluable | high | non important | - |
| Vomiting TRAE (grade 3-4) | 0.95 [0.06, 15.31] | | < 1 | | 0% | 2 studies (2/-) | 51.6 % | low | not evaluable | high | non important | - |
| Weight decreased TRAE (grade 3-4) | 0.95 [0.06, 15.31] | | < 1 | | 0% | 2 studies (2/-) | 51.6 % | low | not evaluable | high | non important | - |
